



August 29, 20XX

ACC Health Plan
Attn: Medical Review Office
PO Box 12345
Anytown, USA 11111

Patient Name:
Insurance ID:
Date of Birth:
Facility: 123 Medical Center
Date of Service:
Total Charges:

APPEAL EXAMPLE: Bevacizumab and Nivolumab (pages 1-2)

Diagnosis

C719 Malignant neoplasm of brain Astroblastoma
C71.7 Malignant neoplasm of the brain stem
Z923 Personal history of irradiation

Procedure:

J9035 Injection, Bevacizumab, 10 mg
J9299 Injection, Nivolumab, 1 mg

An appeal is indicated based on a review of clinical documentation in the medical record verifying the need for outpatient Bevacizumab (Avastin) injections. The argument of medical necessity is supported by BCBS: I-86-005 Bevacizumab (Avastin).

Outpatient Bevacizumab (Avastin) injections for a 33-year-old male with diagnosis of Recurrent Anaplastic Diffuse Infiltrating Astrocytoma involving his brainstem. An astrocytoma is a form of glioma tumor which originates from astrocytes. In 2010, he began having pressure in the back of his head with straining. He had a CT and an MRI that revealed an infiltrating lesion involving the pons. A right suboccipital stereo-guided biopsy revealed an infiltrating diffuse astrocytoma. His treatment history included a course of external beam radiation totaling 54 Gy in the summer of 2010. He then received Sodium Valproate, Vorinostat, Sorafenib, Herceptin and Avastin for about 2.5 months that was completed in December 2010. He was observed for some time and began alternative therapy in 2012 with low-dose prednisone and vitamin supplementation. He had disease progression in 2015 and began treatment with Temozolomide. He completed 9 cycles and had progression of disease. He began radiation plus Avastin in January 2016 and also restarted Temozolomide due to worsening of headaches with radiation. He has received Nivolumab (BMS-936558 study) and Bevacizumab (Avastin) every 2 weeks since February 2016. On 4/21/17 his MRI showed stable disease with no progression.

Treatment plan

[Redacted]

BCBS Medical Policy I-86-005: Bevacizumab (Avastin)

[Redacted]

Food and Drug Administration (FDA)

[Redacted]

National Comprehensive Cancer Network (NCCN)

[Redacted]

Regards,

XXXXX

RN, BSN, CCM

Phone: XXX.XXX.XXXX

Email: XXXXX@AdventHP.com